Showing 4,221 - 4,240 results of 18,731 for search 'significantly ((((lower decrease) OR (((a decrease) OR (mean decrease))))) OR (larger decrease))', query time: 0.91s Refine Results
  1. 4221

    Perceived exertion. by JoEllen M. Sefton (16880253)

    Published 2025
    “…</p><p>Conclusions</p><p>Results suggest a powered ankle exoskeleton may decrease energy consumption during military relevant tasks when conducted in a laboratory environment. …”
  2. 4222

    Metabolic cost. by JoEllen M. Sefton (16880253)

    Published 2025
    “…</p><p>Conclusions</p><p>Results suggest a powered ankle exoskeleton may decrease energy consumption during military relevant tasks when conducted in a laboratory environment. …”
  3. 4223

    S1 Graphical abstract - by Aman Goyal (19231397)

    Published 2025
    “…</p><p>Conclusions</p><p>Our analysis showed a significant decrease in mortality from paroxysmal tachycardia since 1999, although there has been a slight increase in recent years. …”
  4. 4224

    3‑Furoic Acid from Sea-Derived Aspergillus luchuensis Hy‑6 as a Valuable Lead Compound against Plant-Parasitic Nematodes in Cucumber by Linsong Wang (6447482)

    Published 2025
    “…Root-knot nematodes pose a significant threat to crop growth and yield, thereby impacting global food security. …”
  5. 4225

    Image 2_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.jpeg by David Qixiang Chen (8198265)

    Published 2025
    “…We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …”
  6. 4226

    Image 1_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.jpeg by David Qixiang Chen (8198265)

    Published 2025
    “…We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …”
  7. 4227
  8. 4228
  9. 4229
  10. 4230
  11. 4231
  12. 4232

    DataSheet1_Significant nocturnal wakefulness after sleep onset in metabolic dysfunction–associated steatotic liver disease.PDF by Sofia Schaeffer (20379954)

    Published 2024
    “…<p>Metabolic dysfunction–associated steatotic liver disease (MASLD) is a multisystemic disease with a multifactorial pathogenesis involving dietary, environmental, and genetic factors. …”
  13. 4233

    DataSheet3_Significant nocturnal wakefulness after sleep onset in metabolic dysfunction–associated steatotic liver disease.PDF by Sofia Schaeffer (20379954)

    Published 2024
    “…<p>Metabolic dysfunction–associated steatotic liver disease (MASLD) is a multisystemic disease with a multifactorial pathogenesis involving dietary, environmental, and genetic factors. …”
  14. 4234

    DataSheet2_Significant nocturnal wakefulness after sleep onset in metabolic dysfunction–associated steatotic liver disease.PDF by Sofia Schaeffer (20379954)

    Published 2024
    “…<p>Metabolic dysfunction–associated steatotic liver disease (MASLD) is a multisystemic disease with a multifactorial pathogenesis involving dietary, environmental, and genetic factors. …”
  15. 4235

    DataSheet4_Significant nocturnal wakefulness after sleep onset in metabolic dysfunction–associated steatotic liver disease.PDF by Sofia Schaeffer (20379954)

    Published 2024
    “…<p>Metabolic dysfunction–associated steatotic liver disease (MASLD) is a multisystemic disease with a multifactorial pathogenesis involving dietary, environmental, and genetic factors. …”
  16. 4236
  17. 4237

    Data Sheet 1_Lack of association between genetic variations in CYP3A5 and blood pressure or hypertension risk in the UK biobank.pdf by Pia Leibold (21390134)

    Published 2025
    “…In a sensitivity analysis based on different racial subgroups, only White participants showed significant associations between the CYP3A5*3 variant and slightly higher DBP (β = 0.10 mmHg, 95% CI: 0.02 to 0.18, P = 0.01), as well as between genotype-predicted CYP3A5 activity score and slightly lower DBP (β = −0.10 mmHg, 95% CI: −0.18 to −0.02, P = 0.01). …”
  18. 4238
  19. 4239
  20. 4240

    Data Sheet 1_The gastric microbiome altered by A4GNT deficiency in mice.zip by Dawei Gong (3070773)

    Published 2025
    “…Background<p>Selective antimicrobial effects have been found for α1,4-linked N-acetylglucosamine residues at the terminus of O-glycans attached to a core protein of gastric gland mucin. A4gnt encodes α1,4-N-acetylglucosaminyl transferase, which is responsible for the biosynthesis of α1,4-linked N-acetylglucosamine. …”